Optimization of colistin dosing regimen for cystic fibrosis patients with chronic Pseudomonas aeruginosa biofilm lung infections

Pediatric Pulmonology
Wang HengzhuangNiels Høiby

Abstract

The present study was performed to explore dosing regimens of colistin in patients of cystic fibrosis (CF) with Pseudomonas aeruginosa chronic biofilm lung infection. Ten CF patients were involved. One dose colistimethate sodium (CMS) of 6 MIU (million international units) and 9 MIU were administered by intravenous infusion over 45 and 90 min. Venous blood was collected at different time points after the infusion of CMS. Pharmacokinetic parameters of colistin were calculated. Minimum inhibitory concentration for planktonic P. aeruginosa, minimum biofilm inhibitory concentration and minimum biofilm eradication concentration of P. aeruginosa were determined. Monte Carlo simulation was performed to determine the clinical probability of target attainment of different dosing regimens of colistin in CF patients. For 90 min (6 MIU), 45 min (6 MIU), and 45 min (9 MIU) intravenous infusion of colistin, Cmax was 8.9 ± 1.8, 15 ± 5.5, and 31.7 ± 5.3 μg/mL, respectively; Tmax was 1.2 ± 0.4, 0.7 ± 0.2, and 0.8 ± 0.2 h, respectively; AUCtot were 31 ± 3.8, 34 ± 10, and 135 ± 31mg · h/L, respectively; t1/2 was 2.1 ± 0.4, 2 ± 0.3, and 3.3 ± 0.4 h, respectively. MBIC and MBEC of colistin on biofilms at 24 h period treatment were 16-128 μg/mL for ...Continue Reading

References

May 1, 1993·Antimicrobial Agents and Chemotherapy·A ForrestJ J Schentag
May 21, 1999·Science·J W CostertonE P Greenberg
Dec 6, 2000·The European Respiratory Journal·G DöringD J Touw
Apr 30, 2002·International Journal of Antimicrobial Agents·D Andes, W A Craig
Jan 27, 2004·Antimicrobial Agents and Chemotherapy·Markus MuellerHartmut Derendorf
Oct 7, 2004·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Gerd DöringUNKNOWN Consensus Study Group
Jun 15, 2011·Antimicrobial Agents and Chemotherapy·Wang HengzhuangNiels Høiby
Feb 23, 2012·Antimicrobial Agents and Chemotherapy·Wang HengzhuangNiels Høiby
Nov 10, 2012·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Gerd DöringUNKNOWN Consensus Study Group
Dec 10, 2013·International Journal of Antimicrobial Agents·Rikke Prejh BrochmannPeter Østrup Jensen
Jan 19, 2015·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·N HøibyUNKNOWN ESCMID Study Group for Biofilms and Consulting External Expert Werner Zimmerli

❮ Previous
Next ❯

Citations

Sep 25, 2020·Pediatric Pulmonology·Adrienne P Savant, Susanna A McColley
Sep 10, 2019·Pediatric Pulmonology·Wang Hengzhuang, Niels Høiby
Jul 10, 2019·Pediatric Pulmonology·Roger L Nation, Cornelia B Landersdorfer
Aug 17, 2019·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Bruna Gaelzer Silva TorresFrederic Tewes
Jun 23, 2021·International Journal of Antimicrobial Agents·Elio CastagnolaFrancesca Mattioli

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Biofilm & Infectious Disease

Biofilm formation is a key virulence factor for a wide range of microorganisms that cause chronic infections.Here is the latest research on biofilm and infectious diseases.

Biofilms

Biofilms are adherent bacterial communities embedded in a polymer matrix and can cause persistent human infections that are highly resistant to antibiotics. Discover the latest research on Biofilms here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Related Papers

Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
E Sans-SerramitjanaM Viñas
Antibiotica Et Chemotherapia. Fortschritte. Advances. Progrès
H SCHOENENBERG
Pediatria
Y CHABBERT de LAJUDIE
JAMA : the Journal of the American Medical Association
W M KIRBY, C E ROBERTS
© 2022 Meta ULC. All rights reserved